• +1-646-491-9876
    • +91-20-67278686

    Search

    Pulmonary Arterial Hypertension-Pipeline Review H2 2017

    Pulmonary Arterial Hypertension-Pipeline Review H2 2017

    • Report Code ID: RW00011060472
    • Category Life Sciences
    • No. of Pages 266
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Pulmonary Arterial Hypertension-Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

    Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 9, 20, 39, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
    -The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 5
    Pulmonary Arterial Hypertension-Overview 6
    Pulmonary Arterial Hypertension-Therapeutics Development 7
    Pulmonary Arterial Hypertension-Therapeutics Assessment 20
    Pulmonary Arterial Hypertension-Companies Involved in Therapeutics Development 32
    Pulmonary Arterial Hypertension-Drug Profiles 55
    Pulmonary Arterial Hypertension-Dormant Projects 244
    Pulmonary Arterial Hypertension-Discontinued Products 246
    Pulmonary Arterial Hypertension-Product Development Milestones 247
    Appendix 256

    List of Tables
    Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Companies, H2 2017 (Contd..3), H2 2017
    Products under Development by Companies, H2 2017 (Contd..4), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Actelion Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Aerogen Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Arena Pharmaceuticals Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Ascendis Pharma A/S, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Asklepion Pharmaceuticals LLC, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by AVEO Pharmaceuticals Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Bial-Portela & Ca SA, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Biogen Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Bristol-Myers Squibb Company, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Camurus AB, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Capricor Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Celsion Corp, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Celtaxsys Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Chiesi Farmaceutici SpA, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Complexa Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Eli Lilly and Company, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Galectin Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by GlaxoSmithKline Plc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by HitGen LTD, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Insmed Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Insys Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Johnson & Johnson, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Liquidia Technologies Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by MannKind Corp, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Mezzion Pharma Co Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Nippon Kayaku Co Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Nippon Shinyaku Co Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Nissan Chemical Industries Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Northern Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Novartis AG, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Peloton Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Pluristem Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Polyphor Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Pulmokine Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Reata Pharmaceuticals Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Respira Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Reviva Pharmaceuticals Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Savara Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Serodus ASA, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Silence Therapeutics Plc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by SteadyMed Therapeutics Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Suda Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Toray Industries Inc, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by United Therapeutics Corp, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Vicore Pharma AB, H2 2017
    Pulmonary Arterial Hypertension-Pipeline by Vivus Inc, H2 2017
    Pulmonary Arterial Hypertension-Dormant Projects, H2 2017
    Pulmonary Arterial Hypertension-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Pulmonary Arterial Hypertension-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    Actelion Ltd
    Aerogen Ltd
    Arena Pharmaceuticals Inc
    Ascendis Pharma A/S
    Asklepion Pharmaceuticals LLC
    AVEO Pharmaceuticals Inc
    Bial-Portela & Ca SA
    Biogen Inc
    Bristol-Myers Squibb Company
    Camurus AB
    Capricor Therapeutics Inc
    Celsion Corp
    Celtaxsys Inc
    Chiesi Farmaceutici SpA
    Chugai Pharmaceutical Co Ltd
    Complexa Inc
    Eli Lilly and Company
    Galectin Therapeutics Inc
    GlaxoSmithKline Plc
    HitGen LTD
    Insmed Inc
    Insys Therapeutics Inc
    Johnson & Johnson
    Liquidia Technologies Inc
    MannKind Corp
    Mezzion Pharma Co Ltd
    Nippon Kayaku Co Ltd
    Nippon Shinyaku Co Ltd
    Nissan Chemical Industries Ltd
    Northern Therapeutics Inc
    Novartis AG
    Peloton Therapeutics Inc
    PhaseBio Pharmaceuticals Inc
    Pluristem Therapeutics Inc
    Polyphor Ltd
    Pulmokine Inc
    Reata Pharmaceuticals Inc
    Respira Therapeutics Inc
    Reviva Pharmaceuticals Inc
    Savara Inc
    Serodus ASA
    Silence Therapeutics Plc
    SteadyMed Therapeutics Inc
    Suda Ltd
    Takeda Pharmaceutical Company Ltd
    Toray Industries Inc
    United Therapeutics Corp
    Vicore Pharma AB
    Vivus Inc

    Request for Sample

    Report Url http://www.reportsweb.com//pulmonary-arterial-hypertension-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//pulmonary-arterial-hypertension-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//pulmonary-arterial-hypertension-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments